Table 2

Univariate and multivariate analysis of associations between clinical and pathological features and overall survival (OS)

Median OS in monthsUnadjusted HR (95% CI)
(univariate)
p ValueAdjusted HR (95% CI)*
(multivariate)
p Value
Gender (male/ female)29.126.71.082 (0.651 to 1.797)0.762
Median age (≥64 years/<64)29.124.41.215 (0.828 to 1.783)0.320
Perinodal extension (yes/no)19.526.71.810 (1.144 to 2.864)0.011
Cyclin D1 (high/low)24.029.11.092 (0.702 to 1.698)0.697
Nuclear β-catenin (yes/no)33.926.01.322 (0.799 to 2.189)0.277
E-cadherin (down/normal)25.126.91.012 (0.554 to 1.851)0.968
T stage (T3/ T1,T2)21.6196.55.065 (2.981 to 8.604)0.0002.759 (1.365 to 5.576)0.005
G grade (G3/ G1,G2)†21.0107.62.672 (1.747 to 4.082)0.0001.614 (0.965 to 2.700)0.068
Vasoinvasion (yes/ no)21.680.12.501 (1.688 to 3.705)0.0001.304 (0.770 to 2.207)0.324
LNN meta (yes/no)23.2193.03.245 (1.972 to 5.340)0.0001.237 (0.649 to 2.359)0.518
LNN ratio (>25%/≤25%)18.559.52.550 (1.703 to 3.816)0.0001.591 (0.936 to 2.704)0.086
Perineural growth (yes/ no)21.244.52.235 (1.466 to 3.408)0.0001.270 (0.786 to 2.051)0.329
EGFR (2+, 3+/0, 1+)20.859.52.145 (1.429 to 3.218)0.0001.678 (1.055 to 2.668)0.029
β-catenin (down/normal)22.941.31.665 (1.114 to 2.488)0.0131.377 (0.856 to 2.216)0.188
  • *Multivariate analysis was carried out with variables with p value ≤0.10 reported in univariate analysis.

  • †G grade indicates tumour differentiation.

  • Bold values indicate a p value <0.5.

  • EGFR, epidermal growth factor receptor; LNN, lymph nodes; OS, overall survival.